Antibody Library Technology Market Segmented By Phage Display, Ribosome Display, Yeast Display, Mammalian Cell Surface Display Technology for Research Applications, Drug Discovery & Development
Industry: Healthcare
Published Date: December-2022
Format: PPT*, PDF, EXCEL
Delivery Timelines: Contact Sales
Number of Pages: 277
Report ID: PMRREP11155
Worldwide revenue from the antibody library technology market stands at US$ 153.3 Mn in 2022, with the global market estimated to surge ahead at a CAGR of 4.0% to reach a valuation of US$ 235.5 Mn by the end of 2033.
|
Antibody Library Technology Market Size (2022) |
US$ 153.3 Mn |
|
Projected Market Value (2033) |
US$ 235.5 Mn |
|
Global Market Growth Rate (2023-2033) |
4.0% CAGR |
|
Market Share of Top 5 Countries |
71.4% |
As assessed by Persistence Market Research, phage display are expected to hold a market value of US$ 87.0 Mn by 2023. Overall, antibody library technology market sales account for approximately 0.11% revenue share in the global antibodies market, which was valued at around US$ 145.7 Bn in 2022.
The global market for antibody library technology recorded a historic CAGR of 2.9% in the last 8 years from 2015 to 2022.
Antibody library technology generates recombinant, highly specific, humanized or fully human monoclonal antibodies, by providing in vitro method, which can be used for required target screening. Antibody libraries are displayed using a variety of display technologies that can improve the specificity and affinity of antigen-binding residues on the antibody or the antigen-binding fragment.
It is anticipated that all areas of antibody libraries, such as library size, affinity maturation, selection techniques, etc., will significantly improve as a result of new display-less technology. In vitro display technologies, however, would cover a wide range of areas, including fundamental research, medical research, industrial research, development, and commercialization.
Antibodies are in high demand as a result of rising demand for highly focused medicines to treat diseases like cancer, rare diseases, and neurological disorders. The widely used targeted therapeutic agent is the antibody. Wider use of antibodies is now possible due to the requirement for improved precision in antibody therapy, particularly in drug discovery. Target identification and validation are the initial steps in the drug discovery process, and antibodies are the industry standard for identifying a particular biomolecule or biological pathway.
Automation is rising and becoming common in life science research owing to the demand for increased productivity, speed, accuracy, and efficiency. Selecting and screening of huge antibody libraries, thus requires automation to identify a single therapeutic target from it. Intelligent antibody library designs and display methods enable the easy selection of monoclonal antibody leads with virtually any specificity.
Wide exploitation of these technologies in nearest future is forecasted to create a huge demand for antibody library technologies over the next decade.
The global market is thus likely to show high growth over the coming years at a CAGR of 4.0% and reach a global market size of US$ 235.5 Mn by 2033.
“Technological Advancements”
New "display less" technologies are being developed as a result of the limitations and shortcomings of conventional molecular display technologies. These approaches have successfully separated antibodies with affinities as low as subnanomolar. E.g. periplasmic expression and cytometric screening (PECS) technology – a display-less technology developed by University of Texas.
Further developments in technologies will allow relatively more and fast automated selection of high affinity binders in less time. This is expected to aid the widespread adoption of antibody library technologies for the discovery and development of therapeutic and diagnostic antibodies to reduce the time of discovery.
Furthermore, researchers are practicing use of different display methods for different stages of development. For instance, many lead discovery programs begin with a large size phage display library and then cell-surface display is applied for final affinity maturation.
Monoclonal Antibodies are extensively used for basic research, biomedical research and therapeutic, diagnostic, prophylactic & analytical applications. Most of the biotechnology companies are subscribing to in vitro antibody library platforms instead of in house in vivo generation of Monoclonal Antibodies, which in turns influences demand of antibody library technology.
“Issues Related to Specificities of Molecular Display Systems”
Even though the phage display system is extensively used for protein and antibody engineering, the technology is highly biased. Moreover, phage display technology is excessively redundant and is more laborious in terms of candidate identification.
Other important caveat of all molecular display systems is the background binding between the display system and the target antibody or protein.
Moreover, a majority of MAB produced using these methods is for research grade, and thus is not used in clinical studies. This has led to the lack of awareness towards regulatory pathways for therapeutic use of MAB produced in vitro.
This presents a significant challenge for small biotechnology companies who have a potential therapeutic MAB candidate, but could not commercialize it due to the lack of full knowledge of regulatory procedures.
Why is the U.S. Market Booming?
“Growing Demand for Antibody Library Technologies”
The U.S. market will account for around 54.5% market share in the global antibody library technology market in 2023. One of the key factors supporting expansion is the region’s high healthcare spending. The rising prevalence of chronic diseases such as blood diseases and cardiovascular diseases is also expected to Increase focus on biomedical, stem cell and cancer research.
As per American Cancer Society estimates in 2018, around 1,735,350 people are diagnosed with cancer in the U.S. and with more than 609,640 cancer deaths. Thus, there is an increasing focus on cancer and stem cell research. Stem cell therapy is a widely used technique to treat cancer and blood-related diseases.
Will Germany Be a Lucrative Market for Global Antibody Library Technology?
“Increasing Healthcare Expenditure in Germany”
Germany will hold around 5.0% market share of the global antibody library technology market in 2023.
The Federal Statistical Office reports that Germany's healthcare spending climbed by 4% from 2017 to 2018 in that country. Healthcare spending in Germany was predicted to account for 11.7% of GDP in 2018. Additionally, it is anticipated that healthcare spending will increase in 2019 to 407.4 billion euros, creating a favourable environment for the development of antibody library technologies.
Additionally, the expansion in Germany is being supported by the presence of businesses like YUMAB GMBH. For the best success rates in drug discovery, YUMAB libraries have more than 100 billion distinct antibodies and cutting-edge in vitro selection procedures. It is anticipated that the growth techniques used by these businesses will support the expansion in Germany.
How is China Emerging as a Prominent Market for Antibody Library Technology?
“Rising Prevalence of Cancer in China”
China market is likely to show high growth over the coming years at a CAGR of 6.2% till the year 2033.
While the US and the UK will continue to take the lead, China or East Asia is predicted to have faster growth. GLOBOCAN reports that 4,285,033 new cases of cancer were reported in China in 2018. Due to the inadequacy of current cancer treatments in light of the increased frequency of the disease, China is promoting the development of antibody libraries in an effort to advance cancer immunotherapy.
279 anti-PD-1 and PD-L1 trials out of 365 that were registered in China in 2019 composed 76% of the country's cancer immunotherapy trials. These numbers show that there are opportunities for greater antibody development and discovery in China, and subsequently throughout East Asia.
Such Instances of antibody library technologies have been recorded in the country, thus propelling the growth of the overall market within China.
Which Technology is Driving Growth of the Global Market?
“Increasing Research and Development Activities”
The phage display segment leads the global market currently and are expected to hold a market value of US$ 87.0 Mn by 2023. Antibody fragments are linked to the bacteriophage coat protein in phage display technology. This allows the production of billions of phage, each of which has the gene encoding the antibody fragment on its coat and displays an antibody fragment with a distinct specificity on its surface.
These extremely diverse phage populations allow for the identification and amplification of antibody fragments with the appropriate specificity and target. With this method, antibody libraries up to 109 fragments in size can be produced. HuCAL (MorphoSys AG), Llama VHH Nave Library (Abzena Plc.), and other phage-displayed antibody libraries are examples of those that are commercially available.
Which Application is Largely Preferred for the Antibody Library Technology Globally?
“Increasing Government Grants and Research Funding”
Drug discovery and development will hold a market share of around 62.7% in 2023. Government funds and research funding are a major source of financing for drug discovery and development in the biological sciences, which drives research and development in antibody library technologies.
For instance, the U.K. government's Department of Business Innovation & Skills (BIS) updated its R&D policy and funded US$304.58 Mn in the "Growth Accelerator" initiative to aid in the commercialization of novel goods. The global growth in funding for antibody-based drug discovery and development is driving up demand for antibody library technologies.
Which End User Offers the Global Market a Profitable Outlook?
“Biopharmaceutical Companies are growing at a Higher Rate”
Biopharmaceutical companies will hold a larger share of about 47.5% with a market value of around US$ 75.7 Mn in 2023. Companies with less money and a smaller scale than biotechnology companies have an influence. Due to their poor performance and subsequent capital-constrained operations, investors are unable to finance small businesses. However, by promoting merger and acquisition activity, this might help the industry.
For instance, Takeda Pharmaceutical acquired Shire plc in January 2019, which is anticipated to raise R&D spending in order to expand its biotechnology platform.
Leading companies in the antibody library technologies market are focusing on different promotional strategies to gain high revenue & expand their sales footprint in emerging countries by different strategies of local market players.
Strategic collaborations, agreements, agreements and research sponsorship are the key strategies adopted by manufacturers to increase the product sales in different geographies.
Key instances include:
|
Attribute |
Details |
|
Forecast Period |
2023-2033 |
|
Historical Data Available for |
2015-2022 |
|
Market Analysis |
USD Million for Value |
|
Key Countries Covered |
|
|
Key Market Segments Covered |
|
|
Report Coverage |
|
|
Key Companies’ Profile |
|
|
Customization & Pricing |
Available upon Request |
Technology:
Application:
End User:
Region:
To know more about delivery timeline for this report Contact Sales
The global market is currently valued at around US$ 153.3 Mn in 2022.
Sales of the market are set to witness growth at a CAGR of 4.0% and be valued at around US$ 235.5 Mn by 2033.
Demand for the market increased at a 2.9% CAGR from 2015 to 2022.
The U.S., Germany, China, Japan, and Italy account for most demand for antibody library technology.
The U.S. will account for 54.5% share of the global market in 2023.
North America will be hold more than half of the global market share in terms of revenue in 2023.
China market is likely to show high growth over the coming years at a CAGR of 6.2% till the year 2033.
The U.K. market is set to expand at a 4.5% CAGR over the forecast period.
Germany will hold around 5.0% market share of the global antibody library technology market in 2023.
The market in India is set to expand at a 4.7% CAGR over the forecast period.
